Genes, synecdoche and the possibility of editing ourselves
By Kurt Cobb,
Resilience
| 05. 20. 2018
Margaret Atwood’s 2003 novel Oryx and Crake depicts the evolution and aftermath of a bioengineered global catastrophe. Whether Atwood at the time was privy to insider knowledge that genetic alteration would become easy to do and ubiquitous or whether she just thought it would make a good premise for a novel, I do not know.
What we have now, however, is a world moving ever forward toward what is being called the democratization of genetic engineering or biohacking for short. Anyone with a credit card and a mailing address can now order their own genetic engineering kit. Meanwhile, in major research laboratories around the world visits from awed reporters are bringing the possibility of fabulous advances in medicine to the attention of the public.
Some 6,000 diseases are thought to be linked to our genetic structure. Could these diseases not only be prevented in newly forming humans in utero, but also cured on the fly in fully fledged humans through means that alter their DNA? The preliminary answer is possibly.
Of course, there is concern that gene manipulation...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...